PB1905: FEASIBILITY OF TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE: RESULTS FROM A SERIES OF 19 PATIENTS

PB1905: FEASIBILITY OF TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE: RESULTS FROM A SERIES OF 19 PATIENTS

Bibliographic Details
Main Authors:	F. KACHA, D. LAMARA, A. BOUDAOUD, A. RABHI, S. ADJA, K. BOUMKHILA, M. SAÏDI
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850472.94101.cd

Similar Items

PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
by: Y. Bouchakor Moussa, et al.
Published: (2022-06-01)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN TUNISIAN CHRONIC MYELOID LEUKEMIA PATIENTS
by: Rim FRIKHA, et al.
Published: (2023-10-01)

Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
by: Carla Boquimpani, et al.
Published: (2022-07-01)

Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
by: Malkan Umit Y., et al.
Published: (2018-12-01)

Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia
by: Ekaterina Yu. Chelysheva, et al.
Published: (2022-08-01)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
by: S.-M. Galdean, et al.
Published: (2022-06-01)

Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study
by: Emine Merve Savaş, et al.
Published: (2023-12-01)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
by: M. J. Ramos, et al.
Published: (2022-06-01)

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
by: Kazuma Ohyashiki, et al.
Published: (2016-04-01)

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
by: Kamal Chamoun, et al.
Published: (2019-01-01)

PB1832: INFLAMMATION INDUCED COAGULATION IN ACUTE MYELOID LEUKEMIA
by: Olivera Mitrović Ajtić, et al.
Published: (2023-08-01)

PB1782: INTEGRATIVE MOLECULAR SUBTYPES OF ACUTE MYELOID LEUKEMIA
by: Qianxing Mo, et al.
Published: (2023-08-01)

Evaluation of tyrosine kinase inhibitor discontinuation initiative in patients with chronic myeloid leukemia at princess noorah oncology center
by: Afnan Mohammed Noor, et al.
Published: (2022-01-01)

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
by: Matteo Dragani, et al.
Published: (2020-11-01)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
by: Frédéric Millot, et al.
Published: (2021-08-01)

Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
by: Hiroshi Ureshino, et al.
Published: (2022-12-01)

PB1847: ACUTE MYELOID LEUKEMIA – IS IT MORE BESIDES GENETIC ABNORMALITIES?
by: M. Urbano, et al.
Published: (2022-06-01)

PB1832: ARTERIAL THROMBOSIS AND ACUTE MYELOID LEUKEMIA – IS THERE A CONNECTION?
by: N. Pantic, et al.
Published: (2022-06-01)

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
by: A. Iurlo, et al.
Published: (2023-03-01)

PB1970: LONG-TERM RESULTS OF THERAPY FOR CHRONIC MYELOID LEUKEMIA: A 20-YEAR ANALYSIS OF THE GIPAP PROGRAM IN RUSSIA
by: Oleg Shukhov, et al.
Published: (2023-08-01)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
by: E. Zerkalenkova, et al.
Published: (2022-06-01)

PB1812: CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA IN PEDIATRIC POPULATION: THE RESULTS OF A MONOCENTRIC EXPERIENCE
by: H. Charfi, et al.
Published: (2022-06-01)

PB1969: PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND CORONAVIRUS DISEASE 2019 IN THE OMICRON ERA
by: Feiyang Qi, et al.
Published: (2023-08-01)

PB1908: COVID-19 INSIGHTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DIAGNOSIS AND TREATMENT
by: V. Musteata
Published: (2022-06-01)

S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY
by: Fabio Efficace, et al.
Published: (2023-08-01)

P682: THE RESULTS OF THE RUSSIAN PROSPECTIVE STUDY OF REDUCTION AND DISCONTINUATION TREATMENT OF TKI (READIT-2020) IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE
by: Margarita Gurianova, et al.
Published: (2023-08-01)

PB1807: THE SIGNIFICANCE OF MOLECULAR RISK FACTORS IN ACUTE MYELOID LEUKEMIA
by: Alla Gordienko, et al.
Published: (2023-08-01)

PB1801: MYCN IS REQUIRED FOR MAINTAINING AN ONCOGENIC CHARACTERISTICS OF LEUKEMIA CELLS IN ACUTE MYELOID LEUKEMIA
by: Nanfang Huang, et al.
Published: (2023-08-01)

PB1784: CYTOGENETIC LANDSCAPE OF 87 MOROCCAN ACUTE MYELOID LEUKEMIA PATIENTS
by: E. M. Mahtat, et al.
Published: (2022-06-01)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
by: M. Sciumè, et al.
Published: (2022-06-01)

P692: IMMUNE FACTORS MAINTAINING TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF IMATINIB
by: P. Kwaśnik, et al.
Published: (2022-06-01)

Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells
by: Paola Pacelli, et al.
Published: (2023-05-01)

PB1975: ABL1 GENE DNA SEQUENCING IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA.
by: Elena Kuzmina, et al.
Published: (2023-08-01)

PB1967: EVALUATION OF A TRIAL OF IMATIB* DOSE TAPERING IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: RESULTS AT 4.5 YEARS
by: Naima Abdennebi, et al.
Published: (2023-08-01)

P702: FIRST INTERIM RESULTS OF THE PROSPECTIVE STUDY OF DOSE REDUCTION AND DISCONTINUATION OF TYROSINE KINASE INHIBITORS (READIT-2020) IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE
by: M. Gurianova, et al.
Published: (2022-06-01)

PB1818: INFLUENCE OF BODY MASS INDEX ON THE OUTCOME IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
by: A. Elazab, et al.
Published: (2022-06-01)

PB1782: ZINC IN THE MODULATION OF THE ANTIPROLIFERATIVE AND CYTOTOXIC EFFECTS OF OLAPARIB IN ACUTE MYELOID LEUKEMIA
by: M. I. Costa, et al.
Published: (2022-06-01)

Chronic myeloid leukemia
by: Susanne Sauβele
Published: (2018-06-01)

Chronic myeloid leukemia
by: Oliver Hantschel, (Coordinating Author)
Published: (2019-06-01)